Skip to main content
. Author manuscript; available in PMC: 2023 Jan 10.
Published in final edited form as: Cancer Discov. 2023 Jan 9;13(1):146–169. doi: 10.1158/2159-8290.CD-22-0416

Figure 5. Enzymatic domain of UTX is dispensable for its tumor suppressive functions in response to Menin-MLL inhibition.

Figure 5.

(A) Schematic of UTX protein. Highlighted are the 8 tetratricopeptide repeats (TPR) (93-385aa) and the histone demethylase (JmjC) domain (1095-1258aa). Three ~500 amino acid long truncations are also represented. (B) Growth competition assay in mouse UtxKO MLL-AF9 leukemia cells expressing different RFP-tagged Utx cDNAs and treated with Menin-MLL inhibitor (MI-503) for 2 or 6 days. Graph shows the relative growth of leukemia cells infected with RFP-tagged Utx cDNAs measured by flow cytometry (mean±SEM, n=3 infection replicates, P-value calculated by Student’s t-test). (C) Principal component analysis (PCA) of gene expression data from UtxKO MLL-AF9 leukemia cells expressing different RFP-tagged Utx cDNAs and treated with vehicle (DMSO) or Menin-MLL inhibitor (MI-503) for 96 hours. (D) Cdkn2c expression (mean normalized read counts) from different Utx truncations in mouse MLL-AF9 leukemia and treated with vehicle (DMSO) or Menin-MLL (MI-503) for 96 hours (mean±SEM, n=3 replicates, P-value calculated by Student’s t-test).